Clayton D. Blankenship, NP

Clayton Blankenship practices at Rheumatology Services Medical Group in Bakersfield, California.

Clayton Blankenship's NPI, 1790178440, was assigned on March 5, 2015. Clayton Blankenship holds California license 95001896.

Clayton Blankenship's primary practice is Rheumatology Services Medical Group, at 8329 Brimhall Rd, Bakersfield, CA 93312 in Kern County. The practice phone is (661) 695-8385.

Clayton Blankenship's primary practice is Rheumatology Services Medical Group in Bakersfield, California. Clayton Blankenship is also affiliated with Adventist Health Bakersfield. The medical group on file is Rheumatology Services Medical Group. Dmand AI also links Clayton Blankenship to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Clayton Blankenship practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Clayton Blankenship's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Clayton Blankenship is licensed in California.

Dmand AI lists arteritis, arthritis, gout, lower back pain, lupus, muscle pain, fibromyalgia, and limb pain, osteoporosis and psoriasis among the conditions Clayton Blankenship treats.

CMS data shows 30,799 Medicare services from Clayton Blankenship across 15 procedure codes in 2024, for 421 Medicare patients. Medicare paid $501,318 for them. Every service was in an office.

CMS counts 421 Medicare patients who saw Clayton Blankenship in 2024. The largest group is 65 to 74, with 212 patients. 75% of them have arthritis, and 75% have high blood pressure. 29% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Clayton Blankenship's median patient age at 60, with 82% women.

In 2024, Clayton Blankenship wrote 3,356 Medicare Part D claims for 376 patients. 85% of them were for generic drugs. CMS names the drug for 3,218 of them, across 33 drugs with 11 or more claims each, at $1,533,886 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Clayton Blankenship for performance year 2024, reported as part of a group. Clayton Blankenship accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Clayton Blankenship as offering telehealth.

CMS Open Payments shows 281 general payments to Clayton Blankenship from 23 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $1,100.